{"disease":{"id":"brain-nervous-system-cancers","name":"brain nervous system cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07126821","title":"A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05859659","title":"Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)","phase":"","overall_status":"RECRUITING","enrollment_count":70000,"lead_sponsor_name":"Yaou Liu","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT07036783","title":"3D Decision Support Tool for Brain Tumour Surgery Development and Validation: Observational Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Fundación Canaria de Investigación Sanitaria","has_results":false},{"nct_id":"NCT06804655","title":"Pharmacoscopy for Patients With Refractory Primary Brain Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT07496073","title":"A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06742593","title":"Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Suzhou Maximum Bio-tech Co., Ltd.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}